JP2004517090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517090A5 JP2004517090A5 JP2002549245A JP2002549245A JP2004517090A5 JP 2004517090 A5 JP2004517090 A5 JP 2004517090A5 JP 2002549245 A JP2002549245 A JP 2002549245A JP 2002549245 A JP2002549245 A JP 2002549245A JP 2004517090 A5 JP2004517090 A5 JP 2004517090A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- amino
- benzazepin
- alaninyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- 238000000034 method Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- RETLCOJLSHBJEZ-JTQLQIEISA-N (5s)-5-amino-3-methyl-2,5-dihydro-1h-3-benzazepin-4-one Chemical compound N[C@@H]1C(=O)N(C)CCC2=CC=CC=C21 RETLCOJLSHBJEZ-JTQLQIEISA-N 0.000 description 11
- RETLCOJLSHBJEZ-UHFFFAOYSA-N 5-amino-3-methyl-2,5-dihydro-1h-3-benzazepin-4-one Chemical compound NC1C(=O)N(C)CCC2=CC=CC=C21 RETLCOJLSHBJEZ-UHFFFAOYSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000003934 aromatic aldehydes Chemical class 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- AYQMNFRCBKOMIA-UHFFFAOYSA-N 1-benzazepin-2-one Chemical compound O=C1C=CC=C2C=CC=CC2=N1 AYQMNFRCBKOMIA-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- -1 nitrogen 1-amino-3-methyl - 2,3,4,5 - tetrahydro - IH-3-benzazepin-2-one Chemical compound 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- FVMQJWDMZWHTEQ-UHFFFAOYSA-N 3-benzazepin-2-one Chemical compound C1=NC(=O)C=C2C=CC=CC2=C1 FVMQJWDMZWHTEQ-UHFFFAOYSA-N 0.000 description 4
- AGMHHPHTPYMULW-UHFFFAOYSA-N 5-hydroxyimino-3-methyl-1,2-dihydro-3-benzazepin-4-one Chemical compound ON=C1C(=O)N(C)CCC2=CC=CC=C21 AGMHHPHTPYMULW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 3
- NAUWUGHLFUVNQH-UHFFFAOYSA-N 3-methyl-2,5-dihydro-1h-3-benzazepin-4-one Chemical compound C1C(=O)N(C)CCC2=CC=CC=C21 NAUWUGHLFUVNQH-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 2
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 2
- IVRQWKMFUDQDHH-LLVKDONJSA-N (5S)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-5-amine Chemical compound N[C@@H]1CN(CCC2=C1C=CC=C2)C IVRQWKMFUDQDHH-LLVKDONJSA-N 0.000 description 2
- XXZPHQDJNRNRCJ-RLJYASMLSA-N (5S)-5-amino-3-methyl-2,5-dihydro-1H-3-benzazepin-4-one (2R)-2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1.N[C@@H]1C(=O)N(C)CCC2=CC=CC=C21 XXZPHQDJNRNRCJ-RLJYASMLSA-N 0.000 description 2
- FCLMPNRBYATJAR-XPTSAGLGSA-N (5s)-5-amino-5-[(2s)-2-aminopropanoyl]-3-methyl-1,2-dihydro-3-benzazepin-4-one Chemical compound C1CN(C)C(=O)[C@](C(=O)[C@@H](N)C)(N)C2=CC=CC=C21 FCLMPNRBYATJAR-XPTSAGLGSA-N 0.000 description 2
- NGEWQZIDQIYUNV-BYPYZUCNSA-N (S)-2-hydroxy-3-methylbutyric acid Chemical compound CC(C)[C@H](O)C(O)=O NGEWQZIDQIYUNV-BYPYZUCNSA-N 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- BNUHOROHUNBPAD-UHFFFAOYSA-N 1-hydroxyimino-3-methyl-3-benzazepin-2-one Chemical compound ON=C1C(=O)N(C)C=CC2=CC=CC=C21 BNUHOROHUNBPAD-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- NTRIXPNQPWVRJU-UHFFFAOYSA-N 3-methyl-1h-3-benzazepin-2-one Chemical compound C1C(=O)N(C)C=CC2=CC=CC=C21 NTRIXPNQPWVRJU-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- JTVVIFFPZNRVRU-UHFFFAOYSA-N n-(2,2-dimethoxyethyl)-n-methyl-2-phenylacetamide Chemical compound COC(OC)CN(C)C(=O)CC1=CC=CC=C1 JTVVIFFPZNRVRU-UHFFFAOYSA-N 0.000 description 2
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- VWLQIRDZHGFUQA-UHFFFAOYSA-N 1,3,4,5,5a,6-hexahydro-3-benzazepin-2-one Chemical compound C1C(NCCC2C1=CC=CC2)=O VWLQIRDZHGFUQA-UHFFFAOYSA-N 0.000 description 1
- WUYVQJOTPXVUIS-UHFFFAOYSA-N 1,3-dihydro-3-benzazepin-2-one Chemical compound C1=CNC(=O)CC2=CC=CC=C21 WUYVQJOTPXVUIS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HUMIEJNVCICTPJ-UHFFFAOYSA-N 2,2-dimethoxy-n-methylethanamine Chemical compound CNCC(OC)OC HUMIEJNVCICTPJ-UHFFFAOYSA-N 0.000 description 1
- ZRHBGRVIKPJCDP-UHFFFAOYSA-N 2-hydroxy-5-nitrobenzaldehyde Chemical compound OC1=CC=C([N+]([O-])=O)C=C1C=O.OC1=CC=C([N+]([O-])=O)C=C1C=O ZRHBGRVIKPJCDP-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- KLQAOIXAMBXYNI-PPHPATTJSA-N 5-amino-3-methyl-2,5-dihydro-1H-3-benzazepin-4-one (5S)-5-amino-3-methyl-2,5-dihydro-1H-3-benzazepin-4-one Chemical compound NC1C(N(CCC2=C1C=CC=C2)C)=O.N[C@@H]2C(N(CCC1=C2C=CC=C1)C)=O KLQAOIXAMBXYNI-PPHPATTJSA-N 0.000 description 1
- YFLAJACUIAQBCX-UHFFFAOYSA-N 5-methyl-1,2,3,5-tetrahydro-3-benzazepin-4-one Chemical compound C1CNC(=O)C(C)C2=CC=CC=C21 YFLAJACUIAQBCX-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24955200P | 2000-11-17 | 2000-11-17 | |
| PCT/US2001/027799 WO2002047671A2 (en) | 2000-11-17 | 2001-11-05 | Lactam compound to inhibit beta-amyloid peptide release or synthesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517090A JP2004517090A (ja) | 2004-06-10 |
| JP2004517090A5 true JP2004517090A5 (cg-RX-API-DMAC10.html) | 2006-08-17 |
| JP4116437B2 JP4116437B2 (ja) | 2008-07-09 |
Family
ID=22943982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002549245A Expired - Fee Related JP4116437B2 (ja) | 2000-11-17 | 2001-11-05 | β−アミロイドペプチドの放出および／または合成を阻害するラクタム化合物 |
Country Status (33)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| UA74849C2 (en) * | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
| CA2603320A1 (en) | 2005-04-08 | 2006-10-19 | Daiichi Sankyo Company, Limited | Pyridylmethylsulfone derivative |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| EP1985615A4 (en) | 2006-01-31 | 2011-12-14 | Api Corp | PROCESS FOR THE PREPARATION OF BENZAZEPINONE |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| CL2008002060A1 (es) * | 2007-07-16 | 2008-11-21 | Wyeth Corp | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. |
| KR101136260B1 (ko) | 2007-08-14 | 2012-04-19 | 일라이 릴리 앤드 캄파니 | 감마-세크레타제 억제제로서의 아제핀 유도체 |
| TW200920362A (en) | 2007-09-11 | 2009-05-16 | Daiichi Sankyo Co Ltd | Alkylsulfone derivatives |
| CN101945853B (zh) | 2007-12-21 | 2014-08-20 | 配体药物公司 | 选择性雄激素受体调节剂(sarm)及其应用 |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| CN102690231B (zh) * | 2012-04-11 | 2014-07-09 | 南京友杰医药科技有限公司 | 治疗阿尔茨海默病潜在药物司马西特的合成方法 |
| EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| EP2892506B1 (en) | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| CA2884309A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| SMT201700595T1 (it) | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP2987496B1 (en) | 2013-04-19 | 2018-08-08 | National University Corporation Okayama University | Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
| EP3212773B1 (en) | 2014-10-29 | 2021-09-15 | Massachusetts Eye and Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
| KR102362222B1 (ko) | 2016-05-16 | 2022-02-11 | 더 제너럴 하스피탈 코포레이션 | 폐 상피 공학에서 인간 기도 줄기 세포 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11590152B2 (en) | 2018-01-26 | 2023-02-28 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| AU2020257397B2 (en) | 2019-04-19 | 2026-02-26 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| EP4076459B1 (en) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| ES3022307T3 (en) | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| CN120225528A (zh) | 2022-09-02 | 2025-06-27 | 默沙东有限责任公司 | 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途 |
| KR20250079227A (ko) | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| KR20250116773A (ko) | 2022-12-14 | 2025-08-01 | 머크 샤프 앤드 돔 엘엘씨 | 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711537B (en) * | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
| AU4707999A (en) * | 1998-06-22 | 2000-01-10 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| AU1569501A (en) * | 1999-11-09 | 2001-06-06 | Eli Lilly And Company | Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis |
| DE60135489D1 (de) * | 2000-11-17 | 2008-10-02 | Lilly Co Eli | Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung |
| UA74849C2 (en) * | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
| UA77165C2 (en) * | 2000-11-17 | 2006-11-15 | Lilly Co Eli | (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition |
-
2001
- 2001-05-11 UA UA2003054408A patent/UA74849C2/uk unknown
- 2001-11-05 PT PT01989070T patent/PT1341531E/pt unknown
- 2001-11-05 AU AU2002243192A patent/AU2002243192B2/en not_active Ceased
- 2001-11-05 DZ DZ013453A patent/DZ3453A1/fr active
- 2001-11-05 EA EA200300580A patent/EA005954B1/ru not_active IP Right Cessation
- 2001-11-05 DK DK01989070T patent/DK1341531T3/da active
- 2001-11-05 CN CNA018221009A patent/CN1486184A/zh active Pending
- 2001-11-05 US US10/416,771 patent/US20050261495A1/en not_active Abandoned
- 2001-11-05 WO PCT/US2001/027799 patent/WO2002047671A2/en not_active Ceased
- 2001-11-05 CA CA2427227A patent/CA2427227C/en not_active Expired - Fee Related
- 2001-11-05 MX MXPA03004292A patent/MXPA03004292A/es active IP Right Grant
- 2001-11-05 BR BR0115427-3A patent/BR0115427A/pt not_active IP Right Cessation
- 2001-11-05 HR HR20030383A patent/HRP20030383B1/xx not_active IP Right Cessation
- 2001-11-05 IL IL15596001A patent/IL155960A0/xx unknown
- 2001-11-05 ES ES01989070T patent/ES2278804T3/es not_active Expired - Lifetime
- 2001-11-05 PL PL362688A patent/PL212199B1/pl unknown
- 2001-11-05 JP JP2002549245A patent/JP4116437B2/ja not_active Expired - Fee Related
- 2001-11-05 SK SK559-2003A patent/SK288065B6/sk not_active IP Right Cessation
- 2001-11-05 HU HU0301842A patent/HU228117B1/hu not_active IP Right Cessation
- 2001-11-05 SI SI200130701T patent/SI1341531T1/sl unknown
- 2001-11-05 CZ CZ20031351A patent/CZ20031351A3/cs unknown
- 2001-11-05 KR KR1020037006721A patent/KR100819679B1/ko not_active Expired - Fee Related
- 2001-11-05 NZ NZ525854A patent/NZ525854A/en not_active IP Right Cessation
- 2001-11-05 DE DE60126132T patent/DE60126132T2/de not_active Expired - Lifetime
- 2001-11-05 EP EP01989070A patent/EP1341531B1/en not_active Expired - Lifetime
- 2001-11-05 AU AU4319202A patent/AU4319202A/xx active Pending
- 2001-11-12 TW TW090128005A patent/TWI305204B/zh not_active IP Right Cessation
- 2001-11-14 AR ARP010105312A patent/AR035927A1/es not_active Application Discontinuation
- 2001-11-15 MY MYPI20015236A patent/MY134559A/en unknown
- 2001-11-16 PE PE2001001142A patent/PE20020802A1/es not_active Application Discontinuation
-
2003
- 2003-05-13 EC EC2003004600A patent/ECSP034600A/es unknown
- 2003-05-15 IL IL155960A patent/IL155960A/en not_active IP Right Cessation
- 2003-05-15 ZA ZA200303789A patent/ZA200303789B/en unknown
- 2003-05-16 NO NO20032236A patent/NO324324B1/no not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100331T patent/CY1106366T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4116437B2 (ja) | β−アミロイドペプチドの放出および／または合成を阻害するラクタム化合物 | |
| JP7734700B2 (ja) | ベータアドレナリンアゴニストの形態及び組成物 | |
| JP2002525371A (ja) | Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン | |
| JPH06508816A (ja) | （ｓ）（＋）−２−エトキシ−４−［ｎ−［１−（２−ピペリジノ−フェニル）−３−メチル−１−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法 | |
| CA2007117A1 (en) | Beta-adrenergic agonists | |
| EP1517893A2 (en) | Process for producing levetiracetam | |
| NO973539L (no) | Prolinderivater anvendelige som inhibitorer for human leukocyttelastase | |
| HU185523B (en) | Method for producing a phenyl-alkyl-aminoethyl-salicylamide | |
| EP0579681A1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| US7217729B2 (en) | Substituted indoles, process for the production thereof and use thereof for combatting pain | |
| JPWO2000048982A1 (ja) | （２ｒ）−２−プロピルオクタン酸の製造方法 | |
| HUP0301862A2 (hu) | Laktámvegyület, a vegyületet tartalmazó gyógyászati készítmény, eljárás elżállítására, köztitermékek és alkalmazása gyógyászati készítmény elżállítására | |
| JP2000511882A (ja) | Ａｃｅ阻害剤及び／またはｎｅｐ阻害剤として有用なｎ―ホルミルヒドロキシルアミン化合物 | |
| JP2005523245A5 (cg-RX-API-DMAC10.html) | ||
| CN1325465C (zh) | 高纯度德伦环烷及其可药用酸加成盐、制备这些化合物的方法以及含有它们的药物 | |
| JPH0848685A (ja) | テラゾシンモノヒドロクロリド及びその製造法並びに該化合物を製造するための中間体 | |
| JP5250205B2 (ja) | トルテロジン、その組成物及び使用、及びその製造方法 | |
| FR2753970A1 (fr) | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique | |
| US20150045556A1 (en) | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto | |
| CA2647163C (en) | Modified macrophage migration inhibitory factor inhibitors | |
| KR20070054749A (ko) | 순수한 온단세트론 하이드로클로라이드 이수화물의 개선된제조 방법 | |
| JP4190288B2 (ja) | （１ｒｓ，２ｒｓ）−２−［（ジメチルアミノ）メチル］−１−（３−メトキシフェニル）シクロヘキサノールを単離および精製する方法 | |
| EP1847536A1 (en) | Synthesis and uses of pyroglutamic acid derivatives | |
| WO1995004043A1 (en) | Optical resolution of gamma-(4-(((1,1-dimethylethoxy)carbonyl)methylamino)-piperidinyl-1)-gamma-oxo-alpha-(phenylmethyl)-butynic acid with (n,s-)cyclohexyl ethylamine | |
| JP3160041B2 (ja) | アミン誘導体の製造方法 |